Free tool
FAERS Monitor: Nuzyra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209817 or its brand name (Nuzyra, Omadacycline Tosylate). Reports on generic versions are filed under their own applications.
Reports
1,716
Serious
997
58% of reports
Hospitalization
422
Death reported
118
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use454
- nausea268
- vomiting166
- drug ineffective128
- diarrhoea125
- incorrect product administration duration95
- dyspnoea88
- rash86
- fatigue73
- death72
- incorrect dose administered69
- hospitalisation62
- pruritus59
- aspartate aminotransferase increased57
- headache55
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2019 | 35 |
| 2020 | 109 |
| 2021 | 145 |
| 2022 | 152 |
| 2023 | 296 |
| 2024 | 348 |
| 2025 | 399 |
| 2026 | 231 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,443 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| incorrect product administration durationSignal | 95 | 54.0 | 44.4 | 4,871 |
| aspartate aminotransferase increasedSignal | 57 | 13.2 | 10.2 | 630 |
| off label useSignal | 454 | 6.4 | 5.9 | 2,132 |
| hospitalisationSignal | 62 | 4.9 | 3.9 | 193 |
| vomitingSignal | 166 | 4.3 | 3.7 | 431 |
| nauseaSignal | 268 | 4.2 | 3.7 | 663 |
| incorrect dose administeredSignal | 69 | 3.7 | 2.9 | 135 |
| rashSignal | 86 | 2.4 | 2.0 | 72 |
| diarrhoeaSignal | 125 | 2.4 | 2.0 | 101 |
| dyspnoea | 88 | 1.9 | 1.6 | 38 |
| pruritus | 59 | 1.9 | 1.5 | 24 |
| drug ineffective | 128 | 1.2 | 1.0 | 4 |
| fatigue | 73 | 1.1 | 0.9 | 1 |
| headache | 55 | 1.1 | 0.8 | 0 |
| death | 72 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.